3.9 Article

Absolute Determination of Single-Stranded and Self-Complementary Adeno-Associated Viral Vector Genome Titers by Droplet Digital PCR

期刊

HUMAN GENE THERAPY METHODS
卷 25, 期 2, 页码 115-125

出版社

MARY ANN LIEBERT, INC
DOI: 10.1089/hgtb.2013.131

关键词

-

资金

  1. NHLBI Gene Therapy Resource Program [HHSN268200748202C]
  2. NHLBI [HL059407-14]
  3. Bill & Melinda Gates Foundation
  4. ReGenX Biosciences

向作者/读者索取更多资源

Accurate titration of adeno-associated viral (AAV) vector genome copies is critical for ensuring correct and reproducible dosing in both preclinical and clinical settings. Quantitative PCR (qPCR) is the current method of choice for titrating AAV genomes because of the simplicity, accuracy, and robustness of the assay. However, issues with qPCR-based determination of self-complementary AAV vector genome titers, due to primer-probe exclusion through genome self-annealing or through packaging of prematurely terminated defective interfering (DI) genomes, have been reported. Alternative qPCR, gel-based, or Southern blotting titering methods have been designed to overcome these issues but may represent a backward step from standard qPCR methods in terms of simplicity, robustness, and precision. Droplet digital PCR (ddPCR) is a new PCR technique that directly quantifies DNA copies with an unparalleled degree of precision and without the need for a standard curve or for a high degree of amplification efficiency; all properties that lend themselves to the accurate quantification of both single-stranded and self-complementary AAV genomes. Here we compare a ddPCR-based AAV genome titer assay with a standard and an optimized qPCR assay for the titration of both single-stranded and self-complementary AAV genomes. We demonstrate absolute quantification of single-stranded AAV vector genomes by ddPCR with up to 4-fold increases in titer over a standard qPCR titration but with equivalent readout to an optimized qPCR assay. In the case of self-complementary vectors, ddPCR titers were on average 5-, 1.9-, and 2.3-fold higher than those determined by standard qPCR, optimized qPCR, and agarose gel assays, respectively. Droplet digital PCR-based genome titering was superior to qPCR in terms of both intra- and interassay precision and is more resistant to PCR inhibitors, a desirable feature for in-process monitoring of early-stage vector production and for vector genome biodistribution analysis in inhibitory tissues.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Biotechnology & Applied Microbiology

Determining the Minimally Effective Dose of a Clinical Candidate Adeno-Associated Virus Vector in a Mouse Model of Hemophilia A

Jenny A. Greig, Melanie K. Smith, Jayme M. L. Nordin, Tamara Goode, Edward A. Chroscinski, Elizabeth L. Buza, Nicole Schmidt, Lisa M. Kattenhorn, Samuel Wadsworth, James M. Wilson

Summary: In a study on hemophilia A mouse model, the minimally effective dose (MED) of gene therapy vector was determined to be 3 x 10(11) GC/kg. Total bilirubin levels increased with higher vector doses, while no significant differences were observed in liver transaminase levels. There were no vector-related gross or histological findings detected.

HUMAN GENE THERAPY (2022)

Article Biotechnology & Applied Microbiology

Neonatal Fc Receptor Inhibition Enables Adeno-Associated Virus Gene Therapy Despite Pre-Existing Humoral Immunity

Makoto Horiuchi, Christian J. J. Hinderer, Hailey N. N. Shankle, Peter M. M. Hayashi, Jessica A. A. Chichester, Casey Kissel, Peter Bell, Cecilia Dyer, James M. M. Wilson

Summary: Advancements in AAV-based gene therapy hold significant potential for treating rare genetic disorders and addressing unmet medical needs. However, the presence of anti-AAV neutralizing antibodies (NAbs) in human populations limits the efficacy of these therapies. By using FcRn-inhibiting monoclonal antibodies, such as M281, pre-existing NAbs can be reduced, allowing for enhanced gene delivery in NAb-positive patients. This study highlights the importance of mitigating humoral immunity to make AAV-based gene therapies effective.

HUMAN GENE THERAPY (2023)

Article Immunology

Immune transgene-dependent myocarditis in macaques after systemic administration of adeno-associated virus expressing human acid alpha-glucosidase

Juliette Hordeaux, Ali Ramezani, Steve Tuske, Nickita Mehta, Chunjuan Song, Anna Lynch, Katherine Lupino, Jessica A. Chichester, Elizabeth L. Buza, Cecilia Dyer, Hongwei Yu, Peter Bell, Jill M. Weimer, Hung Do, James M. Wilson

Summary: Immune responses to human non-self transgenes in adeno-associated virus (AAV) gene therapy candidates in nonhuman primates can be challenging. A gene therapy candidate for Pompe disease consisting of AAVhu68 was developed, and some severe adaptive immune responses to the therapy were observed, with variability between animals. Cardiac toxicity was found to be associated with a specific haplotype, and an immunodominant peptide was identified as a potential cause. Additionally, robust and safe gene transfer was achieved in an animal with low pre-existing neutralizing antibodies.

FRONTIERS IN IMMUNOLOGY (2023)

Article Medicine, Research & Experimental

Lipid nanoparticle-encapsulated mRNA therapy corrects serum total bilirubin level in Crigler-Najjar syndrome mouse model

Jenny A. Greig, Joanna K. Chorazeczewski, Vivek Chowdhary, Melanie K. Smith, Matthew Jennis, James C. Tarrant, Elizabeth L. Buza, Kimberly Coughlan, Paolo G. V. Martini, James M. Wilson

Summary: Crigler-Najjar syndrome is a rare disorder characterized by hyperbilirubinemia and jaundice caused by UGT1A1 mutations. This study investigated the therapeutic potential of lipid nanoparticle-encapsulated hUGT1A1 mRNA therapy in a mouse model and demonstrated that it can effectively reduce bilirubin levels. The results suggest that this treatment modality may be a potential option for Crigler-Najjar syndrome.

MOLECULAR THERAPY-METHODS & CLINICAL DEVELOPMENT (2023)

Article Veterinary Sciences

Adeno-associated virus-vectored erythropoietin gene therapy for anemia in cats with chronic kidney disease

Shelly L. Vaden, Allison R. Kendall, Jonathan D. Foster, Heidi L. New, Jane S. Eagleson, Jacky L. May, Anne M. Traas, Matthew J. Wilson, Beth H. Mcintyre, Christian J. Hinderer, Lauren K. Olenick, James M. Wilson

Summary: The study suggests that SB-001 therapy can effectively treat nonregenerative anemia in cats with CKD, and it is generally well tolerated. However, some cats experienced side effects of hypertension and encephalopathy during the treatment.

JOURNAL OF VETERINARY INTERNAL MEDICINE (2023)

Article Biotechnology & Applied Microbiology

Integrated vector genomes may contribute to long-term expression in primate liver after AAV administration

Jenny A. Greig, Kelly M. Martins, Camilo Breton, R. Jason Lamontagne, Yanqing Zhu, Zhenning He, John White, Jing-Xu Zhu, Jessica A. Chichester, Qi Zheng, Zhe Zhang, Peter Bell, Lili Wang, James M. Wilson

Summary: Through studying nonhuman primates, we discovered limitations in gene therapy for the liver due to the mechanism of transduction affecting performance. Although transgene expression declines and stabilizes over time, high transduction of non-immunogenic transgenes is still possible. AAV-mediated transgene expression in primate hepatocytes occurs in two phases: high but short-lived expression from episomal genomes, followed by lower but stable expression from integrated vectors.

NATURE BIOTECHNOLOGY (2023)

Article Biology

Quantification of human mature frataxin protein expression in nonhuman primate hearts after gene therapy

Teerapat Rojsajjakul, Juliette J. Hordeaux, Gourav R. Choudhury, Christian J. Hinderer, Clementina Mesaros, James M. Wilson, Ian A. Blair

Summary: Deficiency in human mature frataxin protein leads to Friedreich's ataxia. Gene therapy, specifically increasing the expression of heart frataxin protein, offers a potential way to prevent early mortality in patients. Using rhesus macaques, researchers tested the pharmacology of a gene therapy treatment and successfully developed a species-specific quantitative method to analyze protein expression in monkey heart tissue.

COMMUNICATIONS BIOLOGY (2023)

Meeting Abstract Biotechnology & Applied Microbiology

Gene Therapy Candidate Restores Dopamine Levels in Lesch-Nyhan Syndrome

Eileen Workman, Mariya Kostiv, Julia Johansson, Christian Hinderer, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

A Knockdown and Replacement Strategy for the Treatment of Charcot Marie Tooth Type 2A

Eileen Workman, Mariya Kostiv, Julia Johansson, Christian Hinderer, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Single-Dose Optimized AAV-Based COVID-19 Vaccine Elicits Durable and Protective Immunity Against Variants of Concern in Nonhuman Primates

Nerea Zabaleta, Urja Bhatt, Cecile Herate, Pauline Maisonnasse, Jessica A. Chichester, Julio Sanmiguel, Cheikh Diop, James M. Wilson, Roger Le Grand, Luk H. Vandenberghe

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Long-Term Evaluation of the Efficacy of Intracerebroventricularly Injected AAVhu68 Encoding Human Codon Optimized ARSA (hARSA) Transgene in a Mouse Model of Metachromatic Leukodystrophy (MLD)

Gourav R. Choudhury, Juliette Hordeaux, Christopher Petucci, Brianne Jeffrey, Melissa White, Tamara Goode, Hongwei Yu, Peter Bell, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Toxicity of Frataxin Overexpression in Nonhuman Primates Treated with Intravenous and MRI-Guided Intracerebellar Infusion of an AAV Vector

Christian Hinderer, Rod Miller, Cecilia Dyer, Isaac Chen, Elizabeth Buza, Fe Wright, Phil Latourette, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Electrophysiology and Soluble Biomarker as Translational Tools to Monitor Adeno-Associated-Virus Related Ganglionopathy

Juliette Hordeaux, Lane H. Wilson, Elizabeth L. Buza, Casey L. Kissel, Nicole Maertzig, Cecilia D. Dyer, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Determining the Minimum Effective Dose (MED) of a Clinical Candidate AAV Vector Encoding Engineered Alpha-Galactosidase A Transgene in a Mouse Model of Fabry Disease

Juliette Hordeaux, Chunjuan Song, Tobias Willer, Yanchun Li, Pai-Chi Tsai, Daniel Ellsworth, Peter Bell, Hongwei Yu, Monika Mittal, Jill Weimer, Hung Do, James M. Wilson

MOLECULAR THERAPY (2022)

Meeting Abstract Biotechnology & Applied Microbiology

Application of Single-Cell Transcriptomics to Assess rAAV-Delivered Transgene Expression

Richard J. Lamontagne, Rucha Fadnavis, Anne Mentzinger, Jenny A. Greig, James M. Wilson

MOLECULAR THERAPY (2022)

暂无数据